Astena Holdings (8095) · FactShift to new modalities and outsourcing
Novel-drug makers’ shift away from dependence on long-listed products and acceleration of acquisitions and alliances
First written in FY2018-Q2. . Latest entry: FY2022.
3entries
6years
0from disclosures
How it moved
Same theme, other companies
Accelerating acquisitions and partnerships by innovative drugmakers to move away from dependence on long-listed productsA theme 1 companies write about · 0 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2022Shift to new modalities and outsourcingAnnual report
「In the pharmaceutical CDMO market, pharmaceutical companies are focusing on R&D for new modalities, while partnerships with ventures, including through open innovation, are increasing for small-molecule drugs.」
The market shift away from new-drug manufacturers' dependence on long-listed products has taken concrete form in the growth of new modalities, venture partnerships and outsourced small-molecule CMC activities. - FY2018Progress in focusing on new drug developmentAnnual report
「New drug manufacturers are also increasingly focusing on new drug development, including through the sale of long-listed products and M&A.」
The sale of long-listed products by new drug manufacturers and their focus on new drug development, including M&A, were described as part of the market structure. - FY2018-Q2First statedAnnual report
「New drug manufacturers are also moving away from reliance on long-listed products, and acquisitions and alliances involving domestic and overseas companies for next-generation drug development are accelerating.」
The market structure in which new drug manufacturers are moving away from reliance on long-listed products and accelerating acquisitions and alliances involving domestic and overseas companies for next-generation drug development was disclosed for the first time.